GLP-1 injections reduce appetite and increase feelings of fullness, which can enhance the effectiveness of low-calorie meal replacements by helping you feel satisfied with fewer calories
Tirzepatide for adults living with obesity
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
Survodutide is another dual GLP-1/glucagon agonist in development
This threshold is commonly set around 75%
Trobisch gave me his honest opinion about the procedure I was interested in